Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06061809 · ClinicalTrials.gov registry record · Phase 2

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

A Phase 2 study of Glioblastoma, sponsored by ImmunityBio.

Recruiting
Registry status
Phase 2
Development phase
34
Enrollment target
4
Study locations

NCT06061809: Recruiting Phase 2 study of Glioblastoma, sponsored by ImmunityBio.

NCT06061809 is a Phase 2 study of Glioblastoma that is actively recruiting participants, run by ImmunityBio. The registered enrollment target is 34 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (69% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06061809, a Phase 2 study of Glioblastoma, is actively recruiting participants, sponsored by ImmunityBio.

RECRUITING
Registry status
Phase 2
Development phase
34 participants
Enrollment target
4
Study locations

Study Summary

This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. The phase 2B portion is an open-label, randomized study to evaluate the efficacy and safety for the following 2 experimental arms in participants with recurrent or progressive GBM: NAI, bevacizumab, and TTFields combination therapy (Arm A) or NAI, PD-L1 t-haNK, bevacizumab, and TTFields combination therapy (Arm B). Phase 2 Treatment for all enrolled participants will consist of repeated cycles of 28 days for a maximum treatment period of 76 weeks (19 cycles) as follows: Every 2 weeks (Days 1 and 15 of a 28-day cycle) Fourteen (14) participants were enrolled in the phase 2 portion of this study as of the date of this v02 protocol. No additional participants will be administered therapy in phase 2. Phase 2B Participants will be randomized 1:1 to 1 of 2 experimental arms (Arm A or Arm B). Treatment for all enrolled participants will consist of repeated 8-week cycles for a maximum treatment period of up to 80 weeks (10 cycles). Experimental Arm (A): Every 2 weeks (Days 1, 15, 29, and 43 of an 8-week cycle) Up to twenty (20) participants will be randomized in phase 2B (up to 10 participants/arm. Duration of Treatment: Participants will receive study treatment for up to 76 weeks during phase 2 (up to 19 repeated 28-day cycles) and for up to 80 weeks (up to 10 repeated 8-week cycles) during phase 2B or until they report unacceptable toxicity (not corrected with dose reduction), withdraw consent, or if the Investigator feels it is no longer in the participant's best interest to continue treatment. Treatment may also be discontinued if the participant has confirmed PD per iRANO, unless the participant is clinically stable and is considered potentially deriving benefit per Investigator's assessment. Duration of Follow-up: Participants wh

Primary Outcome

TEAEs and SAEs graded using the NCI CTCAE v5.0

Conditions Studied

Glioblastoma

Interventions

  • DRUG Bevacizumab
  • DRUG N-803
  • DRUG PD-L1 t-haNK
  • DEVICE Tumor Treating Fields (TTFields, 200 kHz)

Study Locations (4)

California

  • Chan Soon-Shiong Institute for Medicine (CSSIFM) - El Segundo
  • Providence Medical Foundation - Fullerton
  • Hoag Memorial Hospital Presbyterian - Newport Beach

Tennessee

  • Vanderbilt-Ingram Cancer Center - Nashville

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2024-08-07
Est. Completion 2030-12-31
Phase Phase 2
ImmunityBio

46 total trials

What NCT06061809 shows while recruiting

NCT06061809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (69% lower).

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.

NCT06061809 reports a single indexed study location in California, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06061809 about?

NCT06061809 is a clinical study titled "N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma". This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. The phase 2B portion is an open-label, randomized study to evalua...

What is the current status of trial NCT06061809?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2024-08-07. Estimated completion is 2030-12-31.

What conditions does trial NCT06061809 study?

This clinical trial studies the following conditions: Glioblastoma.

What interventions are being tested in trial NCT06061809?

The interventions under investigation include: Bevacizumab (DRUG), N-803 (DRUG), PD-L1 t-haNK (DRUG), Tumor Treating Fields (TTFields, 200 kHz) (DEVICE).

Who is sponsoring clinical trial NCT06061809?

This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06061809 being conducted?

This trial has 4 study locations across California, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06061809's enrollment target sits among peer trials

34 119th of 199 higher than 81 of 199 other Glioblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06061809

Source: ClinicalTrials.gov NCT06061809, the US trial registry maintained by the National Library of Medicine. NCT06061809 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.